Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 14/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 8/20 | 0.33 |
| ▸ | CA9 | Q16790 | 7/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA7 | P43166 | 3/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27876125 | 0.92 | FAAH (0.38) | FAAHCA2PRKCACA1CA9 | |
| SCHEMBL27738968 | 0.90 | FAAH (0.41) | FAAHCA2PRKCACA1CA9 | |
| SCHEMBL29130496 | 0.87 | GNAI3 (0.38) | FAAHCA2PRKCA | |
| SCHEMBL6048632 | 0.86 | L3MBTL1 (0.35) | FAAH | |
| SCHEMBL28752430 | 0.86 | THRB (0.38) | FAAHCA2PRKCA | |
| SCHEMBL27424270 | 0.86 | GNAO1 (0.40) | FAAHCA2PRKCA | |
| SCHEMBL28463231 | 0.85 | L3MBTL1 (0.33) | — | |
| SCHEMBL9009668 | 0.84 | L3MBTL1 (0.37) | — | |
| SCHEMBL28519204 | 0.83 | L3MBTL1 (0.32) | — | |
| SCHEMBL465060 | 0.81 | LMNA (0.39) | CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776447-B2 | METHOD FOR PRODUCING OXO-VINYL-IONOL AND O-PROTECTED DERIVATIVES THEREOF | BASF SE (DE) | 2022-01-05 | — | — | EP | claimed |
| EP-2776447-B1 | METHOD FOR PRODUCING OXO-VINYL-IONOL AND O-PROTECTED DERIVATIVES THEREOF | BASF SE (DE) | 2018-05-30 | — | — | EP | claimed |
| US-9061982-B2 | Process for the preparation of oxovinylionol and its O-protected derivatives | BASF SE (DE) | 2015-06-23 | — | — | US | claimed |
| US-20130116473-A1 | PROCESS FOR THE PREPARATION OF OXOVINYLIONOL AND ITS O-PROTECTED DERIVATIVES | BASF SE (DE) | 2013-05-09 | — | — | US | claimed |
| EP-2776447-B2 | METHOD FOR PRODUCING OXO-VINYL-IONOL AND O-PROTECTED DERIVATIVES THEREOF | BASF SE (DE) | 2022-01-05 | — | — | EP | disclosed |
| US-9061982-B2 | Process for the preparation of oxovinylionol and its O-protected derivatives | BASF SE (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20130116473-A1 | PROCESS FOR THE PREPARATION OF OXOVINYLIONOL AND ITS O-PROTECTED DERIVATIVES | BASF SE (DE) | 2013-05-09 | — | — | US | disclosed |
| US-20090270416-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-2038257-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS CHK1 INHIBITORS FOR THE TREATMENT OF CANCER | Sentinel Oncology Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008139152-A1 | N-OXIDE-CONTAINING PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008059259-A2 | ANTICANCER COMPOUNDS WITH A BENZO ( 1, 2, 4 ) TRIAZIN-3YL-AMINE CORE | SENTINEL ONCOLOGY LIMITED (GB) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007144579-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS CHK1 INHIBITORS FOR THE TREATMENT OF CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116473-A1 | PROCESS FOR THE PREPARATION OF OXOVINYLIONOL AND ITS O-PROTECTED DERIVATIVES | HAO2, VAT1, SOD3 | FAAH 3321/4885CA2 948/4885PRKCA 3954/4885 |
| US-20090270416-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER | CHEK1, CHEK2, CDK1 | FAAH 3853/4885CA2 1136/4885PRKCA 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.